Optimized viral dose and transient immunosuppression enable herpes simplex virus ICP0-null mutants To establish wild-type levels of latency in vivo.

Source:http://linkedlifedata.com/resource/pubmed/id/10846077

Download in:

View as

General Info

PMID
10846077